(Q53510666)

15 May 2018

title

Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. (English)

1 reference

15 May 2018

1 reference

1 reference

1 reference

9

1 reference

15 May 2018

author name string

Bianchi G

1

1 reference

15 May 2018

Loguercio C

2

1 reference

15 May 2018

Sgarbi D

3

1 reference

15 May 2018

Abbiati R

4

1 reference

15 May 2018

Chen CH

5

1 reference

15 May 2018

Di Pierro M

6

1 reference

15 May 2018

Disalvo D

7

1 reference

15 May 2018

Natale S

8

1 reference

15 May 2018

publication date

1 June 2000

1 reference

15 May 2018

Digestive and Liver Disease

published in

1 reference

15 May 2018

volume

32

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

398-405

1 reference

15 May 2018

Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Epidemiology of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Health assessment for chronic HCV infection: results of quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

The Italian SF-36 Health Survey: translation, validation and norming

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Effects of cost sharing on seeking care for serious and minor symptoms. Results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Prevalence by Self-report questionnaire and recognition by nonpsychiatric physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

Side effects of high-dose interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980260-1

7 January 2021

10.1016/S1590-8658(00)80260-1

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018